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Abstract
The phase 1-2 study CO-338-010 (Study 10; NCT01482715) is evaluating single-agent rucaparib, a poly(ADP-ribose)
polymerase inhibitor, administered orally to patients with an advanced solid tumor. In the dose escalation phase (Part 1),
we characterized the single-dose and steady-state pharmacokinetic profiles of rucaparib administered once daily (QD;
dose range, 40-500 mg; n = 16) or twice daily (BID; dose range, 240-840 mg; n = 30). Across all dosing schedules
examined, the plasma exposure of rucaparib was approximately dose proportional; half-life was approximately 17 hours,
and median time to maximum concentration (tmax) ranged from 1.5 to 6.0 hours after a single dose and 1.5 to 4.0 hours
following repeated dosing. The steady-state accumulation ratio ranged from 1.60 to 2.33 following QD dosing and 1.47
to 5.44 following BID dosing. No effect of food on rucaparib pharmacokinetics was observed with a single dose of
40 mg (n = 3) or 300 mg (n = 6). In a phase 2 portion of the study (Part 3), the pharmacokinetic profile of rucaparib
was further evaluated at the recommended phase 2 dose of 600 mg BID (n = 26). The mean (coefficient of variation)
steady-state maximum concentration (Cmax) and area under the concentration-time curve from time zero to 12 hours
(AUC0-12h) were 1940 ng/mL (54%) and 16 900 ng  h/mL (54%), respectively. A high-fat meal moderately increased
rucaparib exposure. The fed-to-fasted geometric mean ratios (90% confidence interval [CI]) for AUC0-24h and Cmax
were 138% (117%-162%) and 120% (99.1%-146%); the median (90%CI) tmax delay was 2.5 (0.5-4.4) hours.
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Poly(ADP-ribose) polymerase (PARP) enzymes make
up a 17-member superfamily of nuclear enzymes,
including PARP1, PARP2, and PARP3. Collectively,
these enzymes are activated by and promote the repair
of DNA damage.1,2 PARP inhibition results in the
accumulation of unrepaired single-strand breaks,
which leads to collapsed replication forks and an
accumulation of DNA double-strand breaks.3,4 These
double-strand breaks are repaired by the homologous
recombination repair pathway, in which BRCA1 and
BRCA2 are key proteins that help mediate homologous
recombination repair.5–7 PARP inhibitors may also
induce trapped PARP-DNA complexes, which require
homologous recombination for effective bypass.8
These and other mechanisms account for the synthetic
lethality between PARP inhibition and homologous
recombination repair deficiency.9–11
Rucaparib (formerly known as CO-338, AG-014447,
or PF-01367338) is an oral, small-molecule inhibitor
of PARP1, PARP2, and PARP3.12,13 Rucaparib has
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demonstrated antitumor activity in various tumor
types, including ovarian, breast, and pancreatic
cancers.14–16 Rucaparib is approved by the US Food
and Drug Administration as monotherapy for the
maintenance treatment of adult patients with recurrent
epithelial ovarian, fallopian tube, or primary peritoneal
cancer who are in a complete or partial response to
platinum-based chemotherapy and for treatment of
patients with deleterious BRCA1 or BRCA2 mutation
(germline and/or somatic) associated advanced ovarian
cancer who have been treated with 2 chemotherapies.
The metabolism of rucaparib has been studied in
vitro (Clovis Oncology, Inc., data on file). Rucaparib
showed slow metabolic turnover rates in incubation
with human hepatocytes and liver microsomes. Recom-
binant human cytochrome P450 (CYP) 2D6 and, to
a lesser extent, CYP1A2 and CYP3A4 were able to
metabolize rucaparib.
Patients with different phenotypes of CYP2D6
(poor metabolizers, n = 9; intermediate metabolizers,
n = 71; normal metabolizers, n = 76; and ultra-rapid
metabolizers, n = 4) showed similar clearance (CL)
of rucaparib based on a population pharmacokinetic
analysis. Similarly, no apparent effect of CYP1A2
polymorphisms on the pharmacokinetics of rucaparib
was observed (normal metabolizers, n = 28; hyper-
inducers, n = 136).17 Enzymes that contribute to the
metabolism and elimination of rucaparib have not
been identified in vivo or in humans.
CO-338-010 (Study 10; NCT01482715) is a phase 1-
2 clinical trial evaluating oral rucaparib administered
as continuous monotherapy to patients with advanced
solid tumors, including high-grade ovarian cancer.14 In
Study 10, the recommended phase 2 dose (RP2D) of
rucaparib 600 mg twice daily (BID) was established in
patients with solid tumors. Subsequently, theRP2Dwas
evaluated for safety and efficacy in women with high-
grade ovarian cancer.14
Study 10 also evaluated the single-dose and steady-
state pharmacokinetic profiles of oral rucaparib when
administered once daily (QD) or BID. The effect of a
high-fat meal on the pharmacokinetic profile of ruca-
parib was also evaluated after a single dose (40 mg,
300 mg, or 600 mg) was administered. Intensive phar-
macokinetic data were collected from patients with
solid tumors to evaluate the clinical pharmacokinetics
of rucaparib at the RP2D. The comprehensive pharma-
cokinetic profile of single-agent rucaparib is reported
herein.
Methods
Study Design and Patients
Study 10 is an ongoing, 3-part, open-label, phase 1-
2 study that is evaluating single-agent oral rucaparib
(ClinicalTrials.gov identifier, NCT01482715). Study 10
was approved by the institutional review board at each
study site (see Supporting Information) and is be-
ing conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice Guidelines of the
International Conference on Harmonisation. Patients
provided written consent before participating in the
study.
Study 10 Part 1 enrolled patients aged18 years who
had an advanced solid tumor that progressed on stan-
dard treatment and had an Eastern Cooperative Oncol-
ogy Group Performance Status of 0 to 1. For the dose
escalation portion of the study, a standard 3 + 3 design
was used. A starting dose of 40 mg QD was used, fol-
lowed by escalations to 80, 160, 300, and 500 mg QD,
followed by further escalation to 240, 360, 480, 600, and
840 mg BID. The primary objectives of this portion
of the study were to characterize the safety and phar-
macokinetic profile of oral rucaparib (40-mg, 60-mg,
and/or 120-mg tablets) administered QD or BID con-
tinuously and to establish the maximum tolerated dose
and RP2D in patients with an advanced solid tumor.
Study 10 Parts 2A and 2B evaluated the efficacy and
safety of oral rucaparib at the RP2D in patients with
recurrent, high-grade, serous or endometrioid ovarian
cancer (including primary peritoneal and fallopian tube
cancers) with a BRCA1 or BRCA2 mutation.
Study 10 Part 3 enrolled patients with a relapsed
solid tumor that was associated with a germline or so-
matic BRCA1 or BRCA2 mutation (detected by local
or central testing). The primary objectives of this por-
tion of the study were to assess the pharmacokinetic
profile of rucaparib, the effect of a high-fat meal on
pharmacokinetics, and the safety profile of rucaparib at
the RP2D (600 mg BID) using a higher strength tablet
(300 mg).
For this analysis, pharmacokinetic data from pa-
tients in Parts 1 and 3 were used to evaluate the clinical
pharmacokinetics of rucaparib at the RP2D.
In Study 10 Parts 1 and 3, patients were treated in
continuous 21-day cycles. Two immediate-release ruca-
parib camsylate tablet formulations were used. In Part
1, a lower-strength tablet formulation (40- or 60-mg ru-
caparib equivalence) was administered at dose levels
ranging between 40 and 840 mg. In Part 3, a 300-mg
rucaparib tablet formulation was used for the pharma-
cokinetic evaluation at the RP2D (600 mg BID).
Pharmacokinetic Sample Analysis
Plasma concentrations of rucaparib were deter-
mined by Q Squared Solutions BioSciences (Ithaca,
New York; formerly Advion Bioanalytical Labora-
tories) using validated liquid chromatography and
tandem mass spectrometric methods. Blood sam-
ples were collected in tubes containing dipotassium
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ethylenediaminetetraacetic acid. A 96-well protein
precipitation extraction procedure was developed to
isolate the analyte from plasma samples of 20- or
50-μL aliquots. The resulting samples were subject
to liquid chromatography–tandem mass spectrom-
etry analysis using a selected reaction monitoring
(SRM) method with deuterium-labeled rucaparib
(d7-rucaparib) as the internal standard. The liquid
chromatography consisted of a Polaris C18-A column
(2.1 mm × 50 mm; 3 μm, Agilent Technologies, Santa
Clara, California) and an isocratic elution with 20%
acetonitrile and 0.1% formic acid in water at a flow
rate of 500 μL/min. The tandem mass spectrometry
consisted of an AB SCIEX API4000 system (SCIEX,
Framingham, Massachusetts) and was operated with
Analyst version 1.4.2 in Turbo-ion Spray (400°C) and
positive ionization mode (1800 V). Nitrogen was used
as the curtain gas, ion source gas, and collision gas. Ru-
caparib and d7-rucaparib were quantified by SRMs of
m/z 324.1→ 293.1 andm/z 331.2→ 300.2, respectively.
The concentration range for quantitation was initially
0.5 to 1000 ng/mL and was later switched to a higher
range (5–10 000 ng/mL). Plasma concentrations below
the lower limit of quantitation of either 0.5 or 5 ng/mL
were treated as “0”when calculating summary statistics.
Pharmacokinetics Evaluation
Pharmacokinetics Design. In Part 1, single-dose and
steady-state pharmacokinetics were evaluated on cycle
1 day 1 and day 15, respectively, at rucaparib 40 mg
to 500 mg QD and 240 mg to 840 mg BID. The effect
of a high-fat meal on the pharmacokinetics of ru-
caparib was assessed at 40 mg and 300 mg in 2 co-
horts in Part 1, in which patients received a single dose
of rucaparib under fasting conditions on cycle 1 day
–7 and a single dose of rucaparib following a high-fat
meal on cycle 1 day 1. Under fasted conditions, pa-
tients fasted overnight for 10 hours before predose
assessments followed by administration of rucaparib.
Under fed conditions, patients fasted overnight for10
hours before predose assessments and then consumed a
high-fat, high-calorie meal in the clinic 30minutes prior
to administration of oral rucaparib. The meal con-
tained approximately 800 to 1000 calories total, with
approximately 500 to 600 calories from fat, approxi-
mately 250 calories from carbohydrates, and approx-
imately 150 calories from protein. Under fasted and
fed conditions, no water and no food was allowed for
2 and 4 hours, respectively, following administra-
tion of rucaparib. Continuous QD doses of rucaparib
were administered to all patients enrolled in the food ef-
fect evaluation cohorts beginning on cycle 1 day 2, and
steady-state pharmacokinetics was obtained on cycle 1
day 15.
In Part 3, the effect of a high-fat meal on the phar-
macokinetics of rucaparib after a single 600-mg dose
was also evaluated. In this food effect assessment, pa-
tients were randomized to one of the following se-
quences: sequence 1, fed on cycle 1 day –7 and then
fasted on cycle 1 day 1; or sequence 2, fasted on cycle 1
day –7 and then fed on cycle 1 day 1. Thus, the single-
dose pharmacokinetics was evaluated on cycle 1 day –7
and cycle 1 day 1. Patients then started to receive ru-
caparib 600 mg BID on cycle 1 day 2 with or without
food, and steady-state pharmacokinetics was evaluated
on cycle 1 day 15.
Serial blood samples for full pharmacokinetic profile
generation were obtained from patients during cycle 1
day –7 (Part 1: food effect cohorts only; Part 3: all pa-
tients), cycle 1 day 1 (Parts 1 and 3: all patients), and
cycle 1 day 15 (Parts 1 and 3: all patients) prior to dos-
ing and at 15 (±2) minutes, 30 (±3) minutes, 1 hour (±5
minutes), 1.5 hours (±5 minutes), 2.5 hours (±5 min-
utes), 4 hours (±15 minutes), 6 hours (±15 minutes),
8 hours (±15 minutes), 10 hours (±30 minutes), and
24 hours (±30 minutes) after dosing. For patients in the
BID dose cohorts, the 24-hour sample was collected ap-
proximately 24 hours after the morning dose on day 1
or day 15 and prior to the next morning dose. Blood
samples for trough concentrations were collected prior
to dosing on cycle 1 day 8 and cycle 1 day 22 (or cycle 2
day 1).
Analysis Populations. A patient was included if he or
she had sufficient pharmacokinetic data to derive 1
primary pharmacokinetic parameter and had no major
protocol deviations that would affect pharmacokinetic
evaluation. Analysis of pharmacokinetics was stratified
by study part, dosing regimen (QD or BID dose esca-
lation cohorts), and fed/fasted status (food effect anal-
ysis cohorts). For the food effect analysis, only patients
who completed both fed and fasted assessments were
included.
Pharmacokinetic Parameters. Pharmacokinetic pa-
rameters were calculated using noncompartmental
analysis methods in Phoenix WinNonLin (V6.3 or
higher; Certara, Princeton, New Jersey). Actual
pharmacokinetic sampling times were used in the phar-
macokinetic analysis; data points with missing dosing
or sampling time information were excluded from the
analysis. Plasma concentration values below the lower
limit of quantitation following the same dosewere set as
“0” for the first occurrence and as “missing” thereafter.
Plasma pharmacokinetic parameters were calculated
after a single dose on cycle 1 day –7 and included maxi-
mum plasma concentration (Cmax), time of occurrence
of Cmax (tmax), and area under the concentration-time
curve (AUC) from time 0 to the time (t) of the last
quantifiable concentration (AUC0-t). Parameters cal-
culated after repeated doses (cycle 1 days 1 and 15)
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included Cmax, tmax, minimum plasma concentration
(Cmin), AUC0-t (t = 24 hours for QD dose; t = 10 hours
for BID dose), AUC from time 0 to 12 hours (AUC0-12h)
based on extrapolation (for BID dose), the accumu-
lation ratio of Cmax (Rac Cmax), and accumulation ra-
tio of AUC (Rac AUC) at steady state. The food effect
analysis included fed-to-fasted comparison of Cmax,
tmax, and AUC0-24h. The linear trapezoid rule was used
in the AUC calculation. AUC0-12h at steady state was
derived from pharmacokinetic data up to 10 hours af-
ter dosing using extrapolation.Additional pharmacoki-
netic parameters, such as apparent total plasma CL
at steady state (CLss/F) and elimination half-life (t1/2),
were derived when data allowed.
All statistical analyses were conducted in SAS Ver-
sion 9.3 (SAS Institute, Cary, North Carolina).
Dose Proportionality (Part 1). Dose proportionality on
log-transformed pharmacokinetic parameters derived
at steady state vs the log-transformed dose was assessed
separately for QD and BID doses. The log-transformed
pharmacokinetic parameters and the log-transformed
dose were fitted to the equation:
ln (Y ) = β0 + β1 ln (Dose) + ε
Y represents the Cmax or AUC0-t of one dosing in-
terval at steady state, and ε represents the error with as-
sumed normal distribution. Intercept β0 represents the
coefficient of the dose before the log transformation.
Slope β1, which is the power term of the dose (Doseβ1),
and its 90% confidence interval (CI) were calculated to
assess the dose proportionality.18 The statistical analy-
sis was considered descriptive instead of inferential.
Steady-State Pharmacokinetics. Time to reach the
steady state was evaluated using plasma trough levels
from Part 1 and Part 3, specifically the predose concen-
trations measured on cycle 1 days 8, 15, 16 (24 hours
post day 15 dosing), and 22.Accumulation of rucaparib
at steady state was calculated asRac Cmax andRac AUC
followingQD and BID dosing, respectively. For the QD
dose, AUC0-24h was used to calculate Rac AUC. For the
BID dose, AUC0-12h was used to calculate Rac AUC.
Effect of Food on Pharmacokinetics. In Part 1, pharma-
cokinetic parameters (AUC0-t, Cmax, and tmax) derived
from a single dose of rucaparib 40 mg or 300 mg with
or without a high-fat meal (fed vs fasted) were used for
preliminary assessment of food effect on pharmacoki-
netics. In Part 3, the effect of a high-fat meal (fed vs
fasted) was examined in patients receiving a single dose
of rucaparib 600 mg. Part 3 pharmacokinetic param-
eters (AUC0-t and Cmax) were log-transformed prior to
analysis and were analyzed using a linear mixed-effects
model. The model included food effect, period, and
sequence as fixed effects and the subject as a random
effect. Point estimates (least-squares means) for food
effect and their 90%CIs were calculated on a log scale
and then back-transformed to provide estimates of
and CIs for the geometric mean ratios. The residual
variance from the linear mixed-effects model was
used to calculate the 90%CIs. For tmax, nonparametric
analysis was performed using a Wilcoxon signed-rank
test, and the corresponding 95%CIs for differences in
medians were determined using Walsh averages.
Results
Patients
The first patient was enrolled onDecember 14, 2011; the
visit cutoff dates for this analysis were November 30,
2015 (Part 1), and December 10, 2015 (Part 3). In the
phase 1 dose-escalation portion of Study 10 (Part 1),
56 patients with a locally advanced or metastatic solid
tumor who had progressed on standard treatment were
enrolled. In Part 1, single-dose and steady-state phar-
macokinetics were evaluated in 25 patients who received
rucaparib QD at doses ranging from 40 to 500 mg and
in 30 patients who received rucaparib BID at doses
ranging from 240 to 840 mg (pharmacokinetic analy-
sis; Figure 1). One patient from Part 1 was excluded
from the analysis because the pharmacokinetic profile
was incomplete (only 3 data points during cycle 1 day 1
were reported). The effect of a high-fat meal on single-
dose pharmacokinetics (food effect analysis) was evalu-
ated in 9 patients treated with a single dose of rucaparib
40 mg (n = 3) or rucaparib 300 mg QD (n = 6) (food
effect cohorts).
In the phase 2 pharmacokinetic portion of Study 10
(Part 3), 26 patients with an advanced solid tumor and
evidence of a germline or somatic BRCA1 or BRCA2
mutation were enrolled. All patients received rucaparib
600 mg BID. Full pharmacokinetic profiles were char-
acterized after a single dose of rucaparib was admin-
istered and at steady state. All Part 3 patients were
evaluated for the effect of a high-fat meal on single-
dose pharmacokinetics (food effect analysis). Steady-
state pharmacokinetics (cycle 1 day 15) was evaluated
in 18 patients from Part 3 (Figure 1).
The baseline characteristics of patients who enrolled
in Study 10 Parts 1 and 3 are presented in Table S1.
Part 1 Pharmacokinetics
Overall, a dose-dependent increase in the plasma con-
centration of rucaparib was observed following QD or
BID dosing schedules (Figure 2). At 80 mg QD, ruca-
parib exposure on cycle 1 day 1 appeared to be lower
than what was observed at 40 mg QD, likely due to in-
tersubject pharmacokinetic variability.
In the QD cohorts (40-500 mg), mean Cmax on cycle
1 day 1 (single dose) ranged from 114 to 949 ng/mL,
and AUC0-24h ranged from 800 to 11 000 ng  h/mL
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Part 1 
Phase 1 Dose Escalation
(n = 56)
Incomplete PK Profile 
(n = 1)
40 mg QD (n = 3)
80 mg QD (n = 3)
160 mg QD (n = 4)
300 mg QD (n = 3)
500 mg QD (n = 3)
Part 1 QD 
PK Analysis
(n = 16) 
240 mg BID (n = 3)
360 mg BID (n = 8)
480 mg BID (n = 9)
600 mg BID (n = 7)
840 mg BID (n = 3)
Part 1 BID
PK Analysis
(n = 30) 
600 mg BID (n = 26)
Part 3 BID
PK Analysis
(n = 18) 
600 mg BID (n = 18)
Part 3 BID
Food Effect Analysis
(n = 26) 
40 mg QD (n = 3)
300 mg QD (n = 6)
Part 1 QD PK and 
Food Effect Analysis
(n = 9) 
Part 3 
Phase 2 PK Portion
(n = 26)
Figure 1. Patient flow diagram. BID, twice daily; PK, pharmacokinetics; QD, once daily.
(Table 1). Steady state for the QD dosing schedule was
reached by cycle 1 day 8 (Figure 3A). At steady state
(cycle 1 day 15), mean Cmax (range, 138-1390 ng/mL)
and AUC0-24h (range, 1740-19 900 ng  h/mL) exhib-
ited similar dose-dependent increases as a single dose
of rucaparib (Table 1). Median tmax for the Part 1 QD
cohorts ranged from 1.5 to 4 hours, suggesting rela-
tively fast absorption of rucaparib following oral ad-
ministration. Mean t1/2 ranged from 11.0 to 19.9 hours
during cycle 1 day 1 and 19.5 to 33.6 hours during cy-
cle 1 day 15 across all dose levels. Noncompartmen-
tal analysis showed that the percentage of extrapolated
AUC (%AUCex) was <20% for only 3 subjects in the
Part 1 QD cohorts following administration of a single
dose of rucaparib. Therefore, AUC from time 0 extrap-
olated to infinity (AUC) and pharmacokinetic param-
eters related to AUC such as CL/F are not reported.
There was no apparent dose-associated trend in mean
CLss/F reported based on the pharmacokinetic profile
of cycle 1 day 15 (Table 1). The Rac Cmax at steady state
ranged from 1.06 to 1.8 and the Rac AUC0-24h ranged
from 1.6 to 2.33, which was consistent with the corre-
sponding ranges of t1/2 following QD dosing.
Across the BID dose cohorts in Part 1 (240-840 mg
BID), the mean Cmax on cycle 1 day 1 ranged from 219
to 1380 ng/mL and the AUC0-12h ranged from 2800 to
13 200 ng  h/mL (Table 1). Steady state was reached by
cycle 1 day 8 (Figure 3B) for the BID dosing schedule.
At steady state (cycle 1 day 15), mean Cmax ranged from
971 to 3170 ng/mL and AUC0-12h ranged from 9430 to
29 000 ng  h/mL (Table 1). The median tmax ranged
from 1.5 to 6 hours across all dose levels tested. Due to
the limited pharmacokinetics collection duration and
relatively slow elimination of rucaparib, t1/2 was poorly
estimated and is not reported here. Noncompartmental
analysis showed that no subjects in the Part 1 BID co-
horts had a %AUCex <20%; therefore, AUC was not
analyzed, and pharmacokinetic parameters related to
AUC such as CL/F are not reported. Following BID
dosing, the Rac Cmax at steady state ranged from 2.6 to
4.9 and the Rac AUC0-12h ranged from 1.47 to 5.44. Ac-
cumulation following BID dosing was approximately
twice that following QD dosing.
Dose Proportionality
For the QD and BID dosing schedules, dose propor-
tionality was assessed at steady state for both Cmax and
AUC0-t (Figure 4). For the QD dose, the slopes (β1)
of Cmax and AUC0-24h were 0.92 (90%CI, 0.69–1.15;
R2 = 0.795) and 0.98 (90%CI, 0.72–1.25; R2 = 0.775);
for the BID dose, these values were 1.03 (90%CI, 0.42–
1.63; R2 = 0.261) and 1.04 (90%CI, 0.42–1.67; R2 =
0.253), respectively. In both dosing schedules, the slopes
were approximately 1, suggesting that for bothCmax and
AUC0-t, the relationships between dose and exposure
were proportional.
Food Effect (Parts 1 and 3)
Nine patients in Part 1 (3 from the 40mgQD group and
6 from the 300 mg QD group) were evaluated for the
effect of a high-fat meal on single-dose pharmacokinet-
ics (Figure 1). Mean rucaparib plasma concentration
profiles and pharmacokinetic parameters following ad-
ministration of a single dose of rucaparib (Figure 5A;
Table 2) were similar between fed and fasted condi-
tions. Minimal food effect was observed at each dose
level (Figure S1). No formal food effect analysis was
conducted due to the small sample sizes. (Steady-state
pharmacokinetic data without food restriction for
these patients are provided in Figure 5B and Table 3.)
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Figure 2. Rucaparib plasma concentration-time profiles following once daily (QD [A, B]) and twice daily (BID [C, D]) oral adminis-
tration. Error bars represent standard deviation (SD). Adapted from Kristeleit R, Shapiro GI, Burris HA, et al. A phase I-II study of the
oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid
tumors. Clin Cancer Res. 2017;23(15):4095-4106 [Supplementary Appendix, Figures S1 and S2].14
In Part 3, the mean plasma exposure of a sin-
gle dose of rucaparib 600 mg was higher when ad-
ministered with a high-fat meal than under fasted
conditions (Figure 5A; Table 2). The fed-to-fasted
geometric mean ratios (90%CI) were 138% (117%-
162%) and 120% (99.1%-146%) for AUC0-24h and Cmax,
respectively. The median tmax was 7.83 and 4.02 hours
after dosing under fed and fasted conditions, respec-
tively. The median delay of tmax by a high-fat meal
was 2.5 hours (95%CI, 0.500–4.405; P  .05 [Wilcoxon
signed-rank test]). Under fed conditions, the intersub-
ject variability (CV%) of the geometric mean AUC0-24h
was 86.8% and that of the Cmax was 82.8%; these values
were similar under fasted conditions (84.6% and 87.5%,
respectively), suggesting that a high-fat meal did not re-
duce the intersubject pharmacokinetic variability in the
absorption of rucaparib.
Steady-State Exposure at the RP2D (Part 3)
The mean rucaparib plasma concentration at steady
state (cycle 1 day 15) for patients receiving ruca-
parib 600 mg BID in Part 3 is shown in Figure 5B.
Mean (CV%) steady-state Cmax and AUC0-12h were
1940 ng/mL (54%) and 16 900 ng  h/mL (54%), respec-
tively, and median tmax was 1.92 (range, 0-5.98) hours
(Table 3).
Safety (Parts 1 and 3)
In Part 1, the median duration of treatment in pa-
tients with advanced solid tumors was 3.2 months
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oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid
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(range, 1 day to 37.9 months) across all dose levels. The
most common treatment-emergent adverse events (any
grade) were nausea, asthenia/fatigue, vomiting, and
anemia (Table S2). The majority (57.1%) of treatment-
emergent events were grade 1 or 2. No grade 4 events
were reported. Three deaths due to disease progression
were reported.14 No treatment-related deaths were re-
ported in Part 1.14
In Part 3, the median duration of treatment in
patients with relapsed solid tumors was 2.9 months
(range, 8 days to 7.6 months). The most common
treatment-emergent adverse events (any grade) were
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Figure 5. Mean (standard deviation [SD]) rucaparib plasma concentration-time profiles under fasted conditions and with a high-fat
meal following a single dose of rucaparib at 40 and 300 mg (Part 1) and 600 mg (Part 3) (A), and steady-state pharmacokinetic profiles
following rucaparib 40 and 300 mg QD and 600 mg BID with or without food (B). Food effect was evaluated on cycle 1 days –7 and
1. Steady-state pharmacokinetics was evaluated on cycle 1 day 15. BID, twice a day; QD, once daily.
asthenia/fatigue, nausea, decreased appetite, and vom-
iting (Table S2). Four (15.4%) patients died due to a
treatment-emergent adverse event, including 2 (7.7%)
due to disease progression, 1 (3.8%) due to dyspnea, and
1 (3.8%) due to pulmonary embolism. No treatment-
related deaths were reported in Part 3.
Discussion
The intensive pharmacokinetic data collected in Study
10 allowed for sufficient evaluation of the pharma-
cokinetic profile of the PARP inhibitor rucaparib. The
analysis demonstrates that plasma exposure of ruca-
parib is approximately dose proportional across the
entire dose range tested (40–500 mg QD and 240–
840 mg BID).
The estimated t1/2 was approximately 17 (range, 11-
33.6) hours. As the t1/2 values were based on a rel-
atively short pharmacokinetics sampling duration of
24 hours, the t1/2 should be interpreted with caution.
Nevertheless, the observed time to steady state (day 8)
and themagnitude of steady-state accumulation (range,
1.6-2.33 for QD, 1.47-5.44 for BID) are consistent
with the estimated t1/2, suggesting time-independent
pharmacokinetics.
Early data showed that a high-fat meal had minimal
effect on rucaparib pharmacokinetics following single-
dose administration of rucaparib 40 mg or 300 mg.
Given this early finding, patients ingested rucaparib
with or without food at the higher doses evaluated in
Part 1 (dose-escalation portion) and in Part 2 (phase 2
portion) of Study 10, as well as in other Clovis-
sponsored phase 2 or phase 3 trials. Later, a formal
evaluation of food effect was conducted with ruca-
parib 600 mg in Part 3. A high-fat meal moderately in-
creased rucaparib exposure, with the fed-to-fasted ge-
ometric mean ratios (90%CI) of 138% (117%-162%)
and 120% (99.1%-146%) for AUC0-24h and Cmax, re-
spectively, and delayed tmax by a median of 2.5 hours.
The increase in exposure may be due to increased in-
testinal solubility following consumption of a high-fat
meal. Despite the observed moderate food effect on
Cmax and AUC0-24h, collective clinical data indicate that
rucaparib is efficacious with an acceptable safety profile
when administered to patients at 600 mg BID without
food restriction.14,16,19 As a result, the moderate food
effect on pharmacokinetics is not considered clinically
significant; thus, rucaparib can be administered with or
without food.
The intersubject pharmacokinetic variability at the
RP2D was moderate, with 54% CV for both steady-
state Cmax and AUC0-12h. The oral bioavailability of
rucaparib was previously determined to be moderately
low (36%).20 The magnitude of intersubject pharma-
cokinetic variability observed in this study is not un-
common for small molecule oncology drugs with low
to moderate oral bioavailability. Despite the observed
effect of food on rucaparib exposure, there was no ap-
parent difference in intersubject pharmacokinetic vari-
ability when rucaparib was taken with a high-fat meal
vs under fasted conditions.
In this analysis, pharmacokinetics was examined in
patients receiving lower strength tablets (40 mg and
60 mg, Part 1) and higher strength tablets (300 mg,
Part 3). Across all doses and tablet strengths tested,
the tmax was relatively short, with a cohort median tmax
of 1.5 to 6 hours, suggesting relatively fast absorption
with comparable kinetics regardless of dose or tablet
strength. At the RP2D of 600 mg BID, steady-state ru-
caparib exposures were comparable between patients in
Part 1 (60mg tablets) and Part 3 (300mg tablets). These
results suggest similar absorption kinetics between the
two immediate-release formulations that were used in
Study 10.
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Table 2. Summary of Single-Dose Pharmacokinetic Parameters of Rucaparib Administered Under Fed and Fasted Conditions in Food
Effect Cohorts
Dose Visit Statistics Cmax, ng/mL tmax, h AUC0-24h, ng  h/mL t1/2, h
40 mg QD (Part 1) Cycle 1, day –7 fasted n 3 3 3 3
Arithmetic mean 77.9 741 10.6
Arithmetic mean SD 46.4 580 5.3
Arithmetic mean CV% 60 78 50
Median 57.6 4 468 8.16
Min, max 45.2, 131 2.5, 4.05 347, 1410 6.9, 16.6
Cycle 1, day 1 fed n 3 3 2 3
Arithmetic mean 64.8 794 12.6
Arithmetic mean SD 40.7 536 5.3
Arithmetic mean CV% 63 68 42
Median 71.1 2.55 794 12.7
Min, max 21.3, 102 1, 4.08 415, 1170 7.21, 17.8
300 mg QD (Part 1) Cycle 1, day –7 fasted n 6 6 6 4
Arithmetic mean 415 5320 23.5
Arithmetic mean SD 190 2490 10.9
Arithmetic mean CV% 46 47 46
Median 424 4.09 5410 24.1
Min, max 182, 638 2.5, 24.22 2390, 8680 11.9, 33.8
Cycle 1, day 1 fed n 6 6 5 3
Arithmetic mean 502 6890 17.4
Arithmetic mean SD 377 3740 5.9
Arithmetic mean CV% 75 54 34
Median 393 5.95 6000 20.5
Min, max 177, 1210 2.53, 10 2670, 12 100 10.6, 21.1
600 mg BID (Part 3) Fasteda n 26 26 26 19
Arithmetic mean 819 10 000 18.7
Arithmetic mean SD 689 7590 9.9
Arithmetic mean CV% 84 76 53
Median 585 4.02 7050 18.8
Min, max 127, 3100 0.53, 24.83 1110, 33 000 6.65, 52.2
Feda n 26 26 26 11
Arithmetic mean 959 13 900 16.8
Arithmetic mean SD 698 10 300 9.5
Arithmetic mean CV% 73 74 57
Median 746 7.83 10 900 14.4
Min, max 198, 2640 1.5, 24.45 1990, 40 400 7.96, 42.3
Adapted from Kristeleit R, Shapiro GI, Burris HA, et al. A phase I-II study of the oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with
germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res. 2017;23(15):4095-4106 [Supplementary Appendix, Table S1].14
AUC0-24h, area under the plasma concentration-time curve from 0 to 24 hours; BID, twice daily; Cmax,maximum plasma concentration; CV, coefficient
of variation; QD, once daily; SD, standard deviation; t1/2, half-life; tmax, time of occurrence of maximum plasma concentration.
aIn Part 3 patients were randomized to 1 of the following: sequence 1, fed on day –7 and then fasted on cycle 1 day 1; or sequence 2, fasted on day –7
and then fed on cycle 1 day 1.
EstimatedmeanCLss/F ranged from 26.7 to 47.5 L/h
for the QD dosing schedule and 26.2 to 58.6 L/h for the
BID dosing schedule. Given rucaparib’s oral bioavail-
ability of 36%,20 the CLss at tested oral dose levels
was estimated to be 350 mL/min, which is approxi-
mately 24% of the normal liver blood flow rate (1450
mL/min),21 suggesting relatively low systemic elimi-
nation. Following continuous rucaparib 600 mg BID
dosing, median tmax was 1.92 (range, 0-5.98) hours.
Mean (CV%) steady-state Cmax, AUC0-12h, and CLss/F
were 1940 ng/mL (54%), 16 900 ng  h/mL (54%),
and 44.2 L/h (45%), respectively. The steady-state phar-
macokinetic variability appeared to be moderate. Ef-
fects of intrinsic and extrinsic factors on rucaparib
pharmacokinetic variability were evaluated by popula-
tion pharmacokinetic modeling, which will be reported
separately.
To date, there have been no formal drug-drug inter-
action studies in patients to determine the effect of any
metabolic enzymes on rucaparib pharmacokinetics.
In vitro and preliminary in vivo metabolite profiling
data are suggestive of oxidative deamination and
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Table 3. Summary of Steady-State Pharmacokinetic Parameters of Rucaparib in Food Effect Cohorts
Dose Visit Statistics
Cmax,
ng/mL tmax, h
AUC0-t,
ng  h/mL
AUC0-12h,
ng  h/mLa t1/2, h
40 mg QD (Part 1) Cycle 1, day 15 n 3 3 1 2
Arithmetic mean 129 1050 9.23
Arithmetic mean CV% 62 86
Median 103 4 1050 9.23
Min, max 65.3, 220 1, 4.03 1050, 1050 3.63, 14.8
300 mg QD (Part 1) Cycle 1, day 15 n 5 5 3 3
Arithmetic mean 727 13 300 20
Arithmetic mean CV% 79 106 68
Median 444 2.47 5220 27.5
Min, max 341, 1720 1.08, 6 5070, 29 600 4.24, 28.2
600 mg BID (Part 3) Cycle 1, day 15 n 18 18 18 12 12
Arithmetic mean 1940 15 800 16 900 12.6
Arithmetic mean CV% 54 58 54 54
Median 1480 1.92 12 900 14 700 10.9
Min, max 626, 4050 0, 5.98 5400, 34 200 7580, 39 300 5.31, 26.6
AUC0-t, area under the plasma concentration-time curve from 0 to time t (t = 24 hours for QD; t = 10 hours for BID); AUC0-12h, area under the
plasma concentration-time curve from 0 to 12 hours; BID, twice daily; Cmax, maximum plasma concentration; CV, coefficient of variation; QD, once
daily; t1/2, half-life; tmax, time of occurrence of maximum plasma concentration.
aFor the BID dosing schedule, concentration at 12 hours was calculated by extrapolation from last observed concentration in the same dosing interval.
formation of a carboxylic acid metabolite. No conju-
gate metabolite has been identified in vitro or in vivo. A
[14C] rucaparib mass balance and metabolite profiling
study in patients is under way.
Conclusion
Rucaparib pharmacokinetics was characterized in
patients with an advanced solid tumor, including
high-grade ovarian cancer. Rucaparib demonstrated
time-independent and dose-linear pharmacokinetics,
with moderate pharmacokinetic variability over the
dose levels examined. A high-fat meal showedmoderate
but clinically insignificant increases in rucaparib Cmax
and AUC at the recommended clinical dose of 600 mg.
Acknowledgments
Clinical operations support for the study was provided by
Samantha McGuinness. Medical writing and editorial sup-
port, funded by Clovis Oncology, was provided by Nathan
Yardley, PhD, and Shannon Davis of Ashfield Healthcare
Communications (Middletown, Connecticut). All authors
contributed to the conception and design, or acquisition of
data, or analysis and interpretation o data and drafted or re-
vised the article for important intellectual content. All au-
thors approved the final draft for publication.
Funding
The study was funded by Clovis Oncology, Inc. The study
was also supported by the NIHR/Wellcome UCH Clinical
Research Facility, the UCH/UCL Biomedical Research Cen-
tre, and UCL Experimental Cancer Medicine Centre.
Declaration of Conflicting Interests
G.I.S.’s institution received reimbursement of study costs from
Clovis Oncology for this clinical trial. R.S.K. received an
honorarium from Clovis Oncology for attending an advisory
board relating to rucaparib, and her institution received reim-
bursement of study costs from Clovis Oncology for this clini-
cal trial. Y.D. received an honorarium from Clovis Oncology
for attending an advisory board relating to rucaparib, and her
institution received reimbursement of study costs fromClovis
Oncology for this clinical trial. H.G., L.M., S.W., S.G., and
J.X. are employees of Clovis Oncology and may hold stock
or have stock options in the company. S.J.-T. is a former em-
ployee of Clovis Oncology and may hold stock in the com-
pany. No potential conflicts of interest were disclosed by the
other authors.
References
1. Schreiber V, Dantzer F, Ame JC, de Murcia G.
Poly(ADP-ribose): novel functions for an old molecule.
Nat Rev Mol Cell Biol. 2006;7(7):517–528.
2. Ryu KW, Kim DS, Kraus WL. New facets in the
regulation of gene expression by ADP-ribosylation
and poly(ADP-ribose) polymerases. Chem Rev.
2015;115(6):2453–2481.
3. Helleday T, Lo J, van Gent DC, Engelward BP.
DNA double-strand break repair: from mechanistic
12 Clinical Pharmacology in Drug Development 2018, 00(0)
understanding to cancer treatment. DNA Repair. 2007;
6(7):923–935.
4. Helleday T, Petermann E, Lundin C, Hodgson B,
Sharma RA. DNA repair pathways as targets for cancer
therapy. Nat Rev Cancer. 2008;8(3):193–204.
5. Moynahan ME, Chiu JW, Koller BH, Jasin M. BRCA1
controls homology-directed DNA repair. Mol Cell.
1999;4(4):511–518.
6. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required
for homology-directed repair of chromosomal breaks.
Mol Cell. 2001;7(2):263–272.
7. Venkitaraman AR. Cancer susceptibility and the func-
tions of BRCA1 and BRCA2.Cell. 2002;108(2):171–182.
8. Murai J, Huang SY, Renaud A, et al. Stereospecific
PARP trapping by BMN 673 and comparison with ola-
parib and rucaparib. Mol Cancer Ther. 2014;13(2):433–
443.
9. Ashworth A. A synthetic lethal therapeutic approach:
poly(ADP) ribose polymerase inhibitors for the treat-
ment of cancers deficient in DNA double-strand break
repair. J Clin Oncol. 2008;26(22):3785–3790.
10. Helleday T. The underlying mechanism for the PARP
and BRCA synthetic lethality: Clearing up the misunder-
standings.Mol Oncol. 2011;5(4):387–393.
11. Konstantinopoulos PA, Ceccaldi R, Shapiro GI,
D’Andrea AD. Homologous recombination deficiency:
exploiting the fundamental vulnerability of ovarian
cancer. Cancer Discov. 2015;5(11):1137–1154.
12. Wahlberg E, Karlberg T, Kouznetsova E, et al. Family-
wide chemical profiling and structural analysis of
PARP and tankyrase inhibitors. Nat Biotechnol.
2012;30(3):283–288.
13. Thomas HD, Calabrese CR, Batey MA, et al. Preclin-
ical selection of a novel poly(ADP-ribose) polymerase
inhibitor for clinical trial. Mol Cancer Ther. 2007;6(3):
945–956.
14. Kristeleit R, Shapiro GI, Burris HA, et al. A phase I-II
study of the oral poly(ADP-ribose) polymerase inhibitor
rucaparib in patients with germline BRCA1/2-mutated
ovarian carcinoma or other solid tumors. Clin Cancer
Res. 2017;23(15):4095–4106.
15. Domchek SM, Hendifar AE,McWilliams RR, et al. RU-
CAPANC: An open-label, phase 2 trial of the PARP in-
hibitor rucaparib in patients (pts) with pancreatic can-
cer (PC) and a known deleterious germline or somatic
BRCA mutation. J Clin Oncol. 2016;34(15 suppl):abst
4110.
16. Swisher EM, Lin KK, Oza AM, et al. Rucaparib in
relapsed, platinum-sensitive high-grade ovarian carci-
noma (ARIEL2 Part 1): an international, multicentre,
open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–
87.
17. Xiao JJ, GreenM,Ma SC, et al. Population pharmacoki-
netics (PK) of rucaparib (CO-338) in patients with ad-
vanced ovarian cancer (AOC) or other solid tumors. Clin
Pharmacol Ther. 2017;101(S1):S5–S99.
18. Smith BP, Vandenhende FR, DeSante KA, et al. Confi-
dence interval criteria for assessment of dose proportion-
ality. Pharm Res. 2000;17(10):1278–1283.
19. Coleman RL, Oza AM, Lorusso D, et al. Rucaparib
maintenance treatment for recurrent ovarian carcinoma
after response to platinum therapy (ARIEL3): a ran-
domised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2017;390(10106):1949–1961.
20. Wilson RH, Evans TJ, Middleton MR, et al. A
phase I study of intravenous and oral rucaparib in
combination with chemotherapy in patients with ad-
vanced solid tumours. Br J Cancer. 2017;116(7):884–
892.
21. Davies B, Morris T. Physiological parameters in labora-
tory animals and humans. Pharm Res. 1993;10(7):1093–
1095.
Supporting Information
Additional supporting information may be found on-
line in the Supporting Information section at the end
of the article.
